Click on image to view larger version.

Figure 4 Subanalysis of 6 randomized percutaneous coronary intervention trials comparing glycoprotein (GP) IIb/IIIa inhibitor versus placebo, stratifying composite event rates (death, myocardial infarction, or target vessel revascularization) according to peripheral arterial disease (PAD) presence. RRR = relative risk reduction.